How Do You Know If Depression Is Treatment Resistant?

When depression continues despite treatment, it is understandable to wonder whether the condition has become “treatment resistant.” Maybe one antidepressant provided little improvement. Perhaps another helped somewhat, but important symptoms remained. Or you may have spent months trying different approaches without feeling like you are getting where you need to be.

Treatment-resistant depression, often abbreviated as TRD, is a useful clinical concept, but it is not something that can be determined simply by counting prescriptions.

Before deciding that depression is treatment resistant, a psychiatric provider typically needs to look carefully at what treatments have actually been tried, whether they were given an adequate opportunity to work, which symptoms improved, which symptoms remain, whether side effects limited treatment, and whether another psychiatric or medical issue could be affecting the picture.

That evaluation matters because an antidepressant that has not worked as hoped does not necessarily mean that depression is treatment resistant—and treatment-resistant depression does not mean that depression is untreatable.

What Is Treatment-Resistant Depression?

There is not one universally accepted definition of treatment-resistant depression across every research study and clinical setting.

However, a commonly used clinical definition involves major depressive disorder that has not reached adequate improvement or remission after at least two appropriate antidepressant treatment trials at adequate doses and durations.

A 2024 clinical review indexed by the National Library of Medicine describes treatment-resistant depression as an absence of remission despite trials of two or more antidepressant medications. Importantly, the authors also emphasize confirming medication adherence and adequate dose and duration before concluding that treatment resistance is present.

You can review the clinical review on managing resistance and partial response in depression for additional background.

The definition is not perfectly uniform. Research and clinical guidelines have used somewhat different thresholds, which is one reason a psychiatric evaluation is more useful than trying to diagnose TRD based on a simple online checklist.

Treatment Resistant Does Not Mean Untreatable

The phrase “treatment resistant” can sound discouraging. It may sound as though depression itself is refusing treatment or that there are no remaining options.

That is not what the term means.

TRD describes what has happened with treatments attempted so far. It does not predict with certainty how someone will respond to a different medication strategy, psychotherapy, brain stimulation, esketamine, ketamine, or another appropriately selected treatment.

The National Institute of Mental Health continues to study rapidly acting and other approaches for people whose depression has not responded adequately to conventional treatment. The existence of an entire field devoted to difficult-to-treat depression reflects an important point: lack of response to initial treatments can lead to a different treatment strategy rather than the end of treatment.

One Antidepressant Not Working Usually Does Not Tell the Whole Story

People sometimes assume that if their first antidepressant does not work, they have treatment-resistant depression.

That conclusion is usually premature.

Response to antidepressants varies considerably from one person to another. A medication can produce a strong response, partial response, little response, intolerable side effects, or improvement in some symptoms without resolving others.

Even the phrase “didn't work” can mean several different things.

For one person, it may mean there was no noticeable improvement. For another, mood improved but motivation remained very low. Someone else may have felt better but stopped the medication because of side effects. Another person may have discontinued treatment before there was enough time to evaluate its effect.

Those situations are clinically different, which is why a provider needs more information than the name of the medication.

What Counts as an Adequate Antidepressant Trial?

This is one of the most important questions in evaluating possible treatment-resistant depression.

An antidepressant trial generally needs to involve an appropriate medication, an appropriate dose, sufficient duration, and consistent use before a provider can confidently evaluate the response.

There is no universal number of weeks or dose that applies to every antidepressant and every patient. Medication choice, tolerability, diagnosis, age, other medications, medical conditions, and individual response can affect treatment decisions.

This is also why patients should not increase, decrease, combine, or stop psychiatric medications on their own in an effort to determine whether a treatment “really works.” Medication decisions should be made with the prescribing provider.

Duration matters

Many antidepressants do not produce their full therapeutic effect immediately. A person may notice certain changes before others, and providers often evaluate progress over time rather than judging the medication after only a few days.

Dose matters

A medication taken at a dose below the therapeutic range needed for a particular patient may not represent an adequate treatment attempt. On the other hand, side effects can prevent someone from tolerating a higher dose.

If side effects make an adequate trial impossible, that information is still valuable—but it is different from completing an adequate trial and receiving no therapeutic benefit.

Consistency matters

Missed doses and interruptions can make treatment response harder to interpret. This is not about blaming patients. Cost, side effects, forgetfulness, access problems, uncertainty about treatment, and complicated medication schedules can all affect adherence.

Openly discussing those issues helps a provider understand what actually happened during a treatment attempt.

Partial Response Is Different From No Response

Treatment response is not always all-or-nothing.

A person may experience a meaningful improvement without reaching remission. For example, someone might begin sleeping better and have more energy but continue to struggle with depressed mood and loss of interest. Another person may function better at work while still experiencing significant symptoms at home.

Clinicians may use symptom rating scales along with the patient's description of day-to-day functioning to track changes over time.

A partial response can influence what comes next. Depending on the situation, a provider might consider continuing the current strategy, adjusting it, adding another treatment, changing treatments, or reassessing the diagnosis.

Interpersonal Psychiatry's psychiatric medication management services emphasize symptom monitoring, personalized psychiatric evaluation, and collaborative long-term treatment planning rather than treating medication as a one-time prescription.

Why Re-Evaluating the Diagnosis Matters

Persistent symptoms do not always mean that major depressive disorder is simply resistant to treatment.

Sometimes the clinical picture deserves another look.

Depressive symptoms can occur alongside anxiety disorders, trauma-related conditions, ADHD, substance use, sleep disorders, and other mental health concerns. Bipolar disorder can also include depressive episodes, but its treatment considerations differ from those of major depressive disorder.

Physical health conditions, medications prescribed for nonpsychiatric reasons, sleep disruption, alcohol or substance use, and major life stressors can also influence mood and functioning.

A comprehensive evaluation therefore asks more than, “Which antidepressants have you tried?”

It may explore when symptoms began, whether they are continuous or episodic, changes in sleep and energy, anxiety, mood elevation or irritability, substance use, trauma history, medical history, family history, current medications, previous therapy, and how symptoms affect everyday life.

The purpose is not to search for a different diagnosis simply because treatment has been difficult. It is to make sure the treatment plan is addressing the right problem.

What Might a Treatment-Resistant Depression Evaluation Include?

There is no single test that proves someone has treatment-resistant depression.

Instead, evaluation usually involves assembling the treatment history and current clinical picture.

1. Reviewing previous medications

A provider may review which antidepressants were used, approximate doses, duration, benefits, side effects, reasons for stopping, and whether medications were used consistently.

If you are preparing for an evaluation, bringing a medication list can be helpful. Include medications that did not work, medications that helped temporarily, and medications that caused difficult side effects.

2. Identifying what “better” would actually mean

Depression treatment is about more than changing a number on a symptom scale.

A provider may ask whether you are sleeping differently, returning to activities, functioning more consistently at work or school, reconnecting with other people, taking care of daily responsibilities, or experiencing more interest and enjoyment.

Those details help distinguish partial improvement from remission and make treatment goals more meaningful.

3. Reviewing psychotherapy and other treatments

Medication history is important, but it is not the entire treatment history.

Psychotherapy may be an important part of depression care. Interpersonal Psychiatry's treatment services include psychotherapy and counseling alongside psychiatric medication management and other services.

A provider may want to understand which forms of therapy have been tried, how consistently someone participated, what was helpful, and whether treatment addressed relevant issues such as trauma, relationships, stress, or behavioral patterns.

4. Considering medical and psychiatric factors

The evaluation may also consider other diagnoses, physical health, sleep, substance use, current medications, and other factors that could influence symptoms or treatment response.

5. Discussing patient priorities

Two patients with similar symptoms may have different priorities.

One may be most concerned about medication side effects. Another may need a treatment that fits around work or caregiving. Someone else may be open to an advanced treatment but wants to understand exactly what it involves before deciding.

Personalized treatment planning should make room for those priorities.

What Happens If Depression Is Considered Treatment Resistant?

Identifying treatment resistance does not automatically determine the next treatment.

Instead, it can broaden the conversation.

A provider may consider medication changes or augmentation, psychotherapy, or other evidence-based options depending on the individual's history and clinical circumstances.

For appropriately selected patients, advanced depression treatments may also enter the discussion.

Deep TMS

Repetitive transcranial magnetic stimulation uses magnetic pulses to stimulate neural circuits in the brain. The National Institute of Mental Health describes rTMS as a noninvasive brain-stimulation therapy and notes that it is FDA-cleared for treatment-resistant depression.

Interpersonal Psychiatry offers Deep TMS therapy in Kansas through its Overland Park, Lawrence, and Topeka clinics.

Deep TMS does not involve anesthesia and does not expose the entire body to a systemic medication. Whether it is appropriate depends on individual evaluation and the specific clinical situation.

For additional general information, see the NIMH overview of brain-stimulation therapies.

Spravato

Spravato is the brand name for esketamine nasal spray. The current FDA prescribing information indicates Spravato for treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant.

Because of risks that include sedation, dissociation, respiratory depression, abuse, and misuse, Spravato is administered under healthcare supervision and is available through a restricted REMS program. Patients are monitored for at least two hours after administration.

Interpersonal Psychiatry provides Spravato treatment in Kansas at its Overland Park, Lawrence, and Topeka locations for patients evaluated as appropriate candidates.

The FDA prescribing information for Spravato contains the current indication and detailed safety information.

Ketamine therapy

Ketamine is another treatment that may be discussed in difficult-to-treat depression. It is important to distinguish ketamine from Spravato.

Ketamine is FDA-approved as an anesthetic, while IV ketamine use for depression is off-label. Spravato contains esketamine and has specific FDA-approved psychiatric indications.

Interpersonal Psychiatry provides ketamine infusion therapy in a medically supervised clinical setting for patients who are evaluated as appropriate candidates.

Questions to Bring to a Depression Re-Evaluation

You do not need to know whether your depression is treatment resistant before scheduling an evaluation. That is something you and the provider can work through together.

Useful questions may include:

• Have my previous antidepressant trials been adequate in dose and duration?
• Did I have no response, or did I have a partial response?
• Could another condition be contributing to my symptoms?
• How should we measure whether the next treatment is helping?
• Would psychotherapy add something that medication alone has not addressed?
• What medication strategies remain reasonable?
• At what point should we discuss Deep TMS, Spravato, ketamine, or another treatment?
• What risks, side effects, monitoring requirements, and time commitments should I understand?

Writing down previous medications, approximate dates, benefits, side effects, and reasons for stopping them can also make the conversation more productive.

When Persistent Depression Needs Prompt Attention

Depression that is not improving deserves attention even before anyone decides whether it meets a formal definition of treatment resistance.

If symptoms are worsening, daily functioning is declining significantly, or you are concerned about your safety, contact a healthcare professional promptly.

If you are experiencing suicidal thoughts or emotional distress and need immediate support in the United States, call or text 988 to reach the 988 Suicide & Crisis Lifeline. If you or someone else is in immediate danger, call 911 or go to the nearest emergency department.

Frequently Asked Questions About Treatment-Resistant Depression

Does one failed antidepressant mean I have treatment-resistant depression?

Not necessarily. Although definitions vary, treatment-resistant depression is commonly associated with inadequate response to at least two appropriate antidepressant trials. A provider also needs to consider dose, duration, adherence, side effects, diagnosis, and the degree of response.

How many antidepressants must I try before considering TMS or Spravato?

There is no single answer that applies to every treatment, insurance plan, and patient. Clinical candidacy and coverage requirements can differ. A psychiatric provider can review your treatment history and explain which options may be medically appropriate.

Can depression be partially responsive to medication?

Yes. Someone may improve in certain symptoms or areas of functioning without reaching remission. Partial response is clinically meaningful and can influence whether a provider continues, adjusts, augments, or changes treatment.

Is there a blood test for treatment-resistant depression?

There is no single blood test that establishes treatment-resistant depression. Evaluation relies on clinical history, diagnosis, previous treatment response, medication adequacy, current symptoms, functioning, and other relevant health factors.

Does treatment-resistant depression mean my depression is more severe?

Not automatically. Treatment resistance refers primarily to response to previous treatment, while severity describes the intensity and impact of current symptoms. The two can overlap, but they are not interchangeable concepts.

Can treatment-resistant depression still improve?

Yes. Treatment resistance describes previous treatment response, not the certainty of future outcomes. Other medication strategies, psychotherapy, brain stimulation, esketamine, ketamine, or other approaches may be considered depending on the individual situation.

A Careful Evaluation Can Clarify the Next Step

If depression has continued through multiple treatment attempts, it is reasonable to want more than another prescription without understanding why the previous approach fell short.

A thoughtful re-evaluation can clarify what has actually been tried, whether those treatments received an adequate trial, whether there has been partial improvement, whether another condition deserves attention, and which options make sense to consider next.

Interpersonal Psychiatry provides psychiatric evaluation, medication management, psychotherapy, Deep TMS, Spravato, ketamine therapy, and other mental health services through its Kansas offices. In-person care is available in Lawrence, Topeka, and Overland Park, with telehealth across Kansas and Missouri when appropriate.

Patients in the Kansas City area can also learn more about psychiatric care in Overland Park.

If you have questions about persistent depression or want to discuss your treatment history, you can contact Interpersonal Psychiatry to ask about an appointment and the next appropriate step.

This article is for educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Do not start, stop, or change medication without guidance from a qualified healthcare professional.